Please ensure Javascript is enabled for purposes of website accessibility

3 Growth Stocks Near Record Highs That Are Still Worth Buying

By Keith Speights – Aug 27, 2021 at 5:55AM

Key Points

  • One of these stocks is a pioneer in robotic surgery, a field that's only in its early innings.
  • Another is a tech giant with strong momentum across multiple areas.
  • The third stock is a big biotech with soaring sales and a promising pipeline.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Look for the current all-time highs to be broken.

Many investors like to buy high-flying stocks on dips. It's psychologically rewarding in a way. You feel like you're getting a better deal on a stock that has performed really well. 

There are two main problems that can arise with this approach, though. First, you might have to wait a long time for those dips and miss out on some big gains. Second, sometimes the dips are the beginning of a much larger downtrend.

Buying stocks that have recently set all-time highs can actually be a better strategy. It only works, however, when the stocks have room to run. The good news is that there are several great picks on the market right now that meet both criteria. Here are three growth stocks near record highs that are still worth buying.

Three lines with arrows and dollar signs near the arrows against a blue blackground.

Image source: Getty Images.

Intuitive Surgical

Intuitive Surgical's (ISRG -0.77%) shares have soared nearly 30% so far this year. The healthcare stock is only a little under its record level set last week.

It's quite possible that Intuitive Surgical could experience additional momentum in the near future. The company plans to conduct a 3-for-1 stock split in late September, assuming shareholders vote in favor of the move. However, there are much better reasons to consider investing in Intuitive over the long term.

Robotic surgery is still only in its early innings, even though Intuitive has been selling its da Vinci systems for more than two decades. The company could more than quadruple the number of procedures performed with its robotic surgical systems without adding any regulatory clearances or geographical markets.

Further technological innovation should enable Intuitive Surgical to expand its opportunities. The company thinks that it could more than triple its current addressable market by introducing new products and winning additional regulatory clearances.

Microsoft

Like Intuitive Surgical, Microsoft (MSFT -2.08%) stock is only around 1% below its all-time high. Shares of the technology giant have soared more than 35% year to date.

There's a good reason why Microsoft is performing so well. Nearly everything that could go right for the company is going right. It reported 21% year-over-year revenue growth in its latest quarter with earnings per share jumping 49%. All three of the company's business units delivered solid growth, with two of them posting revenue increases of at least 25%.

Can Microsoft keep this momentum going? I think so. The company's Azure cloud business continues to have strong growth prospects. Enterprise system Dynamics 365 is rapidly picking up market share. The new Windows 11 operating system for PCs launches later this year.

Currently, around 5% of the world's gross domestic product (GDP) is related to technology. However, Microsoft CEO Satya Nadella said in the company's recent quarterly update that he expects the percentage to double on a "more accelerated pace" than some have projected. If he's right (and I suspect that he is), Microsoft will likely be a major beneficiary.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (REGN 1.46%) ranks as the biggest winner of these three growth stocks in 2021. The biotech's shares are up nearly 40% year to date -- a record level.

In the second quarter, Regeneron's revenue skyrocketed 163% year over year with adjusted earnings per share vaulting 260% higher. COVID-19 antibody cocktail REGEN-COV served as the big catalyst behind those impressive gains. 

It's a near certainty that REGEN-COV will continue to make a lot of money for Regeneron over the next several months with the delta variant wreaking havoc across the world. But how will the company fare when coronavirus concerns fade? My prediction is Regeneron can keep up its winning ways.

The big biotech's lineup includes several other products with fast-rising sales, notably including autoimmune-disease drug Dupixent and cancer drug Libtayo. Regeneron also has a pipeline that's loaded with promising antibody therapies targeting a wide range of diseases.

Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool's board of directors. Keith Speights owns shares of Intuitive Surgical and Microsoft. The Motley Fool owns shares of and recommends Intuitive Surgical and Microsoft. The Motley Fool recommends the following options: long January 2022 $580 calls on Intuitive Surgical and short January 2022 $600 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals Stock Quote
Regeneron Pharmaceuticals
REGN
$746.96 (1.46%) $10.72
Microsoft Stock Quote
Microsoft
MSFT
$242.33 (-2.08%) $-5.16
Intuitive Surgical Stock Quote
Intuitive Surgical
ISRG
$263.10 (-0.77%) $-2.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.